Skip to main content
Journal cover image

Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.

Publication ,  Journal Article
Erba, HP
Published in: Leuk Res
February 2015

There is no standard of care for older patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive therapy, and prognosis with currently recommended low-intensity therapies (decitabine, azacitidine, and low-dose cytarabine [LDAC]) remains poor. One promising strategy is to combine low-intensity treatments with novel agents. Gemtuzumab ozogamicin, tipifarnib, and barasertib have been investigated in phase 2/3 or 3 trials combined with LDAC, and phase 3 trials are currently investigating sapacitabine plus decitabine, and volasertib plus LDAC in AML. This review discusses current treatment recommendations and the development of combination therapies for older patients unfit for intensive therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Res

DOI

EISSN

1873-5835

Publication Date

February 2015

Volume

39

Issue

2

Start / End Page

183 / 191

Location

England

Related Subject Headings

  • Quinolones
  • Quinazolines
  • Organophosphates
  • Male
  • Leukemia, Myeloid, Acute
  • Immunology
  • Humans
  • Gemtuzumab
  • Female
  • Decitabine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Journal cover image

Published In

Leuk Res

DOI

EISSN

1873-5835

Publication Date

February 2015

Volume

39

Issue

2

Start / End Page

183 / 191

Location

England

Related Subject Headings

  • Quinolones
  • Quinazolines
  • Organophosphates
  • Male
  • Leukemia, Myeloid, Acute
  • Immunology
  • Humans
  • Gemtuzumab
  • Female
  • Decitabine